📰 Pfizer Data News
Pfizer Data News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pfizer Data. Real-time updates on events, politics, business and more.
June 4, 2022
Pfizer Inc. today announced overall survival results from the Phase 3 PALOMA-2 trial, which evaluated IBRANCE® in combination with letrozole compared to placebo plus letrozole for the... | June 4, 2022
October 27, 2021
Today on Feedback, I shared the story of Maddie De Garay, a 12-year old girl who volunteered to participate in...
October 1, 2021
/PRNewswire/ -- Today, the U.S. Food and Drug Administration is announcing two upcoming meetings of its Vaccines and Related Biological Products Advisory...
September 20, 2021
Vaccinated. cnns jason carroll reports, were still waiting for important details about when shots will go into these arms. >> reporter: its information parents of younger children have been waiting for. pfizer sharing data that shows its vaccine is safe for 5 to 11-year-olds and elicits a robust antibody response. >> this is going to make a huge difference in the fight against covid-19 and parents, pediatricians and teachers are waiting for this. >> reporter: pfizer plans to submit its data to t...
August 21, 2021
Pfizer Inc. announced today that the European Commission has approved XELJANZ ® for the treatment of active polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis in patients two years of age and older who have responded inadequately to previous therapy with disease modifying antirheumatic drugs . Two formulations were approved, a tablet and a new oral solution . XELJANZ is the first and only ...
June 17, 2021
Trial demonstrates cumulative incidence of death or respiratory failure through day 28 was 18.1% with tofacitinib compared to 29.0% with placebo, in hospitalized patients with COVID-19 pneumonia Multi-center, randomized, double-blind, placebo-controlled trial conducted across 15 sites in Brazil Tofacitinib is not approved or authorized for the treatment of COVID-19 patients. Tofacitinib should not be used in … Trial demonstrates cumulative incidence of death or respiratory failure through da...
June 13, 2021
Written by rjs, MarketWatch 666The news posted last week for the coronavirus 2019-nCoV (aka SARS-CoV-2), which produces COVID-19 disease, has been surveyed and some important articles are summarized here. The articles are more or less organized with general virus news and anecdotes first, then stories from around the US, followed by an increased number of items from other countries around the globe. Economic news related to COVID-19 is found here.